Full-Time

Lead Enterprise Application Solutions Architect

SAP

United Therapeutics Corporation

United Therapeutics Corporation

Biotech company develops PAH therapies

Compensation Overview

$153k - $205k/yr

Durham, NC, USA + 1 more

More locations: Silver Spring, MD, USA

Hybrid

At least three days per week in the office; in-office requirements may increase based on business needs.

Bachelor's

Category
Sales & Solution Engineering (1)
Required Skills
Microsoft Office
Software Testing
ServiceNow
SAP Products
Visio
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to United Therapeutics Corporation

See people who can refer or advise you

Requirements
  • A bachelor's degree in an applicable field is required.
  • At least 10 years of hands-on SAP functional experience in the FI/CO area is required.
  • At least 4 years of experience supporting and maintaining a live SAP environment is required.
  • Experience with United States generally accepted accounting principles and financial reporting standards is required.
  • Prior experience in accounting or business process solutions consulting is required.
  • Experience delivering results in complex situations is required.
  • Strong verbal and written communication and documentation skills are required.
  • Ability to convert business needs into technical requirements and design robust technical solutions is required.
  • Ability to identify, prioritize, and own high-priority tasks through project delivery timelines is required.
  • Ability to work independently and complete tasks is required.
  • Strong time-management and multitasking skills without compromising quality are required.
  • Ability to develop strong professional relationships and work effectively in a team environment is required.
  • Attention to detail and organizational skills are required.
  • Ability to incorporate comments and feedback into daily activities and meetings is required.
  • Ability to explain technical concepts in writing and through presentations is required.
  • Ability to challenge external consultants and vendors on technical approaches to achieve efficient and creative solutions is required.
  • Proficiency in Microsoft Office, including Microsoft Project, Excel, Word, Visio, and PowerPoint, is required.
  • SAP experience in life sciences and validated systems is required.
  • Experience with accounts-payable automation systems such as ReadSoft, OpenText, or Ariba is required.
Responsibilities
  • Develop, maintain, and continuously improve financial systems architecture that leverages software investments to deliver solutions to business partners.
  • Lead comprehensive solution development involving multiple SAP applications or modules.
  • Serve as a change champion and project manager for complex efforts involving third-party consultants or internal experts.
  • Perform detailed analysis of system requirements spanning multiple SAP modules, build technical knowledge, and construct optimal solution designs.
  • Develop partnerships with stakeholders and manage project activities in accordance with shared stakeholder goals.
  • Complete functional testing and documentation, and implement process improvements including test automation.
  • Review consultant and peer analyses of system issues for alignment with the overall system design.
  • Propose and architect solutions that address system and business-process pain points.
  • Ensure that proper change-management and controls are followed for solution delivery, and improve internal change-management and system-governance processes.
  • Build and maintain workstream priorities and roadmaps, and implement solution components for continuous process efficiency and improvement.
  • Evaluate and improve system controls and control processes.
  • Design solutions for manual processes, including the establishment of system workflows.
  • Partner with workstream business-process owners to construct priority roadmaps and track progress against roadmap items.
  • Identify needs for increased system-user expertise and coordinate training sessions using internal and external resources.
  • Perform all other duties as required.
Desired Qualifications
  • SAP certification is preferred.
  • Experience with S/4HANA and system migration or upgrade efforts is preferred.
  • Experience with SAP Analytics Cloud, Concur, TrinTech or other account-reconciliation software, ServiceNow, and GL Wand is preferred.
United Therapeutics Corporation

United Therapeutics Corporation

View

United Therapeutics develops therapies for life-threatening diseases, with a focus on pulmonary arterial hypertension and rare conditions. Its approved medicines, including Remodulin, Tyvaso, Orenitram, Adcirca, and Unituxin, treat PAH and pediatric neuroblastoma and are delivered by injections, inhalations, or oral tablets. The company also pursues regenerative medicine and xenotransplantation through its Lung Biotechnology PBC and Revivicor units to create bioengineered organs for transplant. It differentiates itself by combining drug development with organ engineering and by operating as a Public Benefit Corporation that balances profits with social and environmental goals, aiming to extend lives and increase access to transplantable organs.

Company Size

N/A

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

1996

Get referred to United Therapeutics Corporation

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approved LungFX on June 29, 2026, with services targeted for 2027.
  • Second-quarter 2026 net income rose to $333 million despite softer revenue.
  • United Therapeutics bought Thymmune for $140 million, expanding transplant-tolerance programs.

What critics are saying

  • Tyvaso net sales fell in Q2 2026 as Yutrepia launches intensified.
  • Liquidia and Boehringer lawsuits threaten Treprostinil revenues and sales execution through 2027.
  • Tyvaso concentration makes a bad PAH cycle or trial failure existential.

What makes United Therapeutics Corporation unique

  • LungFX approval makes United Therapeutics first in centralized EVLP.
  • Thymmune acquisition deepens its organ-tolerance and regenerative-medicine moat.
  • Cash-rich rare-disease franchise funds organ manufacturing and xenotransplantation bets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Holidays

Paid Vacation

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Conference Attendance Budget

Professional Development Budget

Professional Certification Support

Tuition Reimbursement

Stock Options

Company Equity

Employee Stock Purchase Plan

Relocation Assistance

Employee Referral Bonus

Performance Bonus

Profit Sharing

Sabbatical Leave

Hybrid Work Options

Remote Work Options

Flexible Work Hours

ParentAL Leave

Company News

Investor's Business Daily
Aug 12th, 2026
Liquidia drops 4% despite $170M Yutrepia sales beat, misses earnings by 2 cents

Liquidia shares fell more than 4% on Wednesday despite the company's lung disease drug Yutrepia beating second-quarter sales expectations. The treatment generated $170.4 million in sales, growing 31% and surpassing forecasts of $166.4 million. However, the company posted earnings of 74 cents per share, slightly missing expectations of 76 cents. Yutrepia, which launched in June 2025, competes with United Therapeutics' Tyvaso in treating high blood pressure in the lungs. Since launch, Liquidia has received approximately 5,900 new patient prescriptions, with more than 5,000 patients starting treatment. Over 1,100 physicians now prescribe the drug. Liquidia stock has gained 155% year-to-date and ranks second on the IBD 50 list of elite growth stocks.

Yahoo Finance
Aug 7th, 2026
United Therapeutics reports $333M net income and $7.27 EPS as ralinepag files for FDA approval

United Therapeutics reported second-quarter 2026 results showing sales of $783.3 million, a slight year-on-year decline, whilst net income rose to $333 million and diluted earnings per share increased to $7.27. The company continued share repurchases under its $1.50 billion buyback programme, retiring 5.84% of shares. The biotech firm also published positive phase 3 ADVANCE OUTCOMES data for investigational pulmonary arterial hypertension therapy ralinepag and filed with the FDA. The stronger earnings per share partly reflects the shrinking share count from buybacks. Analysts remain divided on the company's future, with some projecting only 1.2% annual revenue growth and $1.4 billion earnings by 2029, citing concerns about its concentrated portfolio of pulmonary drugs and regulatory uncertainties.

Yahoo Finance
Jul 23rd, 2026
United Therapeutics appoints ex-National Academy of Medicine president Victor Dzau to board

United Therapeutics Corporation has appointed Victor Dzau to its board of directors, effective 22 July 2026. Dr Dzau recently completed a 12-year term as president of the National Academy of Medicine and previously served as chancellor for health affairs at Duke University and president of the Duke University Health System. Dr Dzau is recognised globally as a physician-scientist whose research laid the foundation for ACE inhibitors. He pioneered gene therapy for vascular disease and currently studies cardiac regeneration. Martine Rothblatt, chairperson and chief executive officer of United Therapeutics, said Dr Dzau is uniquely capable of guiding the company in its mission of developing transplantable organs and organ alternatives for patients with end-stage organ failure.

Yahoo Finance
Jul 11th, 2026
United Therapeutics wins FDA approval for LungFX device amid questions over valuation

United Therapeutics is under scrutiny after the US FDA approved its LungFX device for centralised ex vivo lung perfusion. The stock has shown strong momentum, with a year-to-date return of 10.13% and a one-year total shareholder return of 85.12%, though short-term prices have eased slightly. The company closed at $547.06, against a narrative fair value of $665.23, suggesting an 18% undervaluation. The valuation gap depends on whether LungFX, Tyvaso, and the broader pulmonary and organ platforms can drive future earnings. United Therapeutics' pipeline includes studies in progressive fibrosis, next-generation delivery platforms, and organ manufacturing technologies. However, the company faces risks from potential trial setbacks and drug pricing reforms that could impact profitability and cash flows.

Yahoo Finance
Jul 8th, 2026
United Therapeutics acquires Thymmune for $140M to advance organ transplant innovation

United Therapeutics Corporation acquired Thymmune Therapeutics for $140 million in cash, with potential additional earn-out payments of up to $160 million tied to clinical and regulatory milestones through 2031. Thymmune develops regenerative thymic cell therapies using human-induced pluripotent stem cells. The acquisition expands United Therapeutics' organ transplantation capabilities. The company focuses on treating life-threatening diseases, including pulmonary arterial hypertension, whilst addressing the global organ shortage through xenotransplantation, 3D bioprinting, and ex vivo lung perfusion technologies. Separately, the FDA granted premarket approval for LungFX, which Leerink Partners described as a regulatory advancement supporting the company's long-term organ manufacturing strategy. Leerink maintains an Outperform rating on United Therapeutics shares.